



A prediction model based on computed tomography characteristics for identifying malignant from benign sub-centimeter solid pulmonary nodules

Shu-Lei Cui^{1#}, Lin-Lin Qi^{1#}, Jia-Ning Liu^{1#}, Feng-Lan Li¹, Jia-Qi Chen¹, Sai-Nan Cheng¹, Qian Xu², Jian-Wei Wang¹

¹Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ²Department of Computed Tomography and Magnetic Resonance, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Contributions: (I) Conception and design: SL Cui, LL Qi, JN Liu, JW Wang; (II) Administrative support: JW Wang; (III) Provision of study materials or patients: SL Cui, LL Qi, JN Liu, FL Li; (IV) Collection and assembly of data: SL Cui, LL Qi, JN Liu, JQ Chen; (V) Data analysis and interpretation: SL Cui, LL Qi, JN Liu, SN Cheng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work as co-first authors.

Correspondence to: Jian-Wei Wang, MD. Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. Email: dr_jianweiwang@163.com; Qian Xu, MD. Department of Computed Tomography and Magnetic Resonance, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang 050000, China. Email: xuqianhb@sina.com.

Background: Distinguishing benign from malignant sub-centimeter solid pulmonary nodules (SSPNs) continues to be challenging in clinical practice. Earlier diagnosis is crucial for improving patient survival and prognosis. This study aimed to investigate the risk factors of malignant SSPNs and establish and validate a prediction model based on computed tomography (CT) characteristics to assist in their early diagnosis.

Methods: A total of 261 consecutive participants with 261 SSPNs were retrospectively recruited between January 2012 and July 2023 from National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Center 1), including 161 malignant lesions and 100 benign lesions. Patients were randomly assigned to the training set (n=183) and validation set (n=78) according to a 7:3 ratio. Malignant nodules were confirmed by pathology; and benign nodules were confirmed by follow-up or pathology. Clinical data and CT features were collected to estimate the independent predictors of malignancy of SSPN with multivariate logistic analysis. A clinical prediction model was subsequently established by logistic regression. Furthermore, an additional 69 consecutive patients with 69 SSPNs from The Fourth Hospital of Hebei Medical University (Center 2) between January 2022 and December 2022 were retrospectively included as an external cohort to validate the predictive efficacy of the model. The performance of the prediction model was assessed by sensitivity, specificity, and the area under the receiver operating characteristic curve.

Results: There were 113 (61.7%), 48 (61.5%) and 28 (40.6%) malignant SSPNs in the training, internal and external validation sets, respectively. Multivariate logistic analysis revealed four independent predictors of malignant SSPNs: tumor-lung interface (P=0.002), spiculation (P=0.04), air bronchogram (P=0.047), and invisible at the mediastinal window (P=0.003). The area under the curve (AUC) for the prediction model in the training set was 0.875 [95% confidence interval (CI): 0.818, 0.933]; and the sensitivity and specificity were 94.7% and 68.6%, respectively. The AUCs in the internal and external validation set were (0.781; 95% CI: 0.664, 0.897) and (0.873; 95% CI: 0.791, 0.955), respectively; the sensitivity and specificity were 66.7% and 83.3% for the internal validation data, and 100.0% and 61.0% for the external validation data, respectively.

Conclusions: The prediction model based on CT characteristics could be helpful for distinguishing malignant SSPNs from benign ones.

Keywords: Solitary pulmonary nodule; computed tomography (CT); differential diagnosis; logistic models

Submitted Dec 23, 2023. Accepted for publication May 24, 2024. Published online Jul 22, 2024.

doi: 10.21037/jtd-23-1943

View this article at: <https://dx.doi.org/10.21037/jtd-23-1943>

Introduction

Lung cancer is responsible for the leading cause of cancer-related mortality. According to estimates from the Global Cancer Statistics 2020, lung cancer accounted for an estimated 1.8 million deaths in 185 countries (1). Most lung cancer cases are already in the advanced-stage when detected or diagnosed, which leads to poor prognosis and short survival time for patients. The survival rate of lung cancer patients decreases with increasing staging. The 5-year survival rate is 68–92% for stage I and 0–60% for stage II–IV (2). The wide utilization of chest computed tomography (CT) has significantly increased the detection rate of pulmonary nodules and reduced lung cancer mortality by 20% (3). The results of low-dose CT for lung cancer screening in Shanghai, China and South Korea showed that 68.3–81.09% of all detected lung cancers were in stage I (4,5). Therefore, earlier detection and diagnosis are key to improving the prognosis of lung cancer patients

and reducing their mortality.

Lung cancer could appear as solid, part-solid, or ground-glass nodules or mass on CT imaging. Compared to part-solid and ground-glass nodules, lung cancer appearing as solid nodules has a higher risk of metastasis and a poorer prognosis (6). Therefore, earlier diagnosis of lung cancer presenting as solid nodules is more crucial. However, the diagnosis of sub-centimeter solid pulmonary nodules (SSPNs) is very difficult in the clinical practice. In most cases, SSPNs are benign, including intrapulmonary lymph nodes, intrapulmonary charcoal deposition, and granuloma; however, 4.5% are malignant (7). In addition, some previous studies have shown that about 10% SSPNs have a risk of lymph node metastasis or recurrence (8,9). However, due to the small diameter of SSPNs, the diagnostic value of positron emission tomography/computed tomography (PET-CT), bronchoscopy, and puncture biopsy is limited (10). Thus, it remains challenging to distinguish malignant from benign SSPNs in clinical practice.

CT examination plays an important role in the diagnosis and follow-up decision-making for these SSPNs. Many studies have investigated the value of the clinical and radiological features in distinguishing between malignant and benign pulmonary nodules. Several predictive models are available to distinguish benign and malignant nodules, such as the Mayo model (11) and the VA model (12). However, these models involved both solid and ground-glass nodules, and rarely only focused on solid nodules, especially SSPNs. This study focused on the SSPNs and collected their clinical and imaging characteristics to construct and validate a risk prediction model, including internal and external dataset from two centers. Therefore, the purpose of this study is to investigate the clinical and imaging characteristics of SSPNs and establish and validate a prediction model based on CT characteristics to assist in their early diagnosis. We present this article in accordance with the TRIPOD reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1943/rc>).

Highlight box

Key findings

- We established a prediction model based on computed tomography (CT) features and validated its performance using data from two centers, which may help in the early diagnosis of lung cancer and improve patient prognosis.

What is known and what is new?

- Tumor-lung interface, spiculation, air bronchogram and invisible at the mediastinal window were independent predictors for distinguishing malignant from benign sub-centimeter solid pulmonary nodules (SSPNs).
- Our model has a good performance in distinguishing malignant SSPNs from benign ones.

What is the implication, and what should change now?

- SSPNs differ from traditional larger nodules both clinically and radiologically.
- The prediction model based on CT features can help distinguish between benign and malignant SSPNs.

Table 1 Pathological subtypes of enrolled nodules in the training and validation sets

Pathological subtypes	N
Benign	100 (38.3%)
Granuloma	20
Fibroplasia	25
Tuberculosis	1
Organising pneumonia	1
Bronchial adenoma	5
Sclerosing pneumocytoma	2
Pulmonary hamartoma	25
Intrapulmonary lymph nodes	11
Hyperplasia of lung tissue	4
Follow-up	6
Malignant	161 (61.7%)
Adenocarcinomas	148
Microinvasive adenocarcinoma	25
Invasive non-mucinous adenocarcinoma	107
Invasive mucinous adenocarcinoma	16
Squamous cell carcinomas	5
Adenosquamous carcinoma	1
Neuroendocrine tumors	7
Carcinoid/neuroendocrine tumor	2
Small cell lung carcinoma	3
Large cell neuroendocrine carcinoma	2

Methods

Patient selection

This retrospective study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the institutional ethics board of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (No. NCC2021C-283) and The Fourth Hospital of Hebei Medical University was informed and agreed with the study. Informed consent was waived as this was a retrospective study and subjects were assured of privacy and identifying information. We retrospectively collected SSPNs between

January 2012 and July 2023 from National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Center 1) with the following criteria: (I) solid pulmonary nodules with mean diameter ≤ 10 mm; (II) malignant or benign SSPNs confirmed by surgical pathology or follow-up: all malignant and a majority of benign nodules were confirmed by surgical pathology; some SSPNs that remained stable during follow-up of ≥ 2 years are considered benign; (III) chest CT images with a thin slice thickness (≤ 1.25 mm). Exclusion criteria were as follows: (I) participants with incomplete clinical data; (II) patients with a history of malignancy in less than 5 years; (III) the pathological diagnoses were metastatic lesions. Finally, we enrolled 261 consecutive patients from Center 1, and randomly divided them at a ratio of 7:3 into two sets: the training set (n=183) and internal validation set (n=78). All of the malignant lesions were pathologically proved, including 148 (148/161, 91.9%) adenocarcinoma, five squamous cell carcinoma, one adenosquamous carcinoma, and seven neuroendocrine tumors (Table 1). Besides, we retrospectively collected 69 patients from The Fourth Hospital of Hebei Medical University (Center 2) between January 2022 and December 2022 as the external validation dataset.

Chest CT scan technique

All CT scans were performed using 64-detector row scanners (Optima CT 660, LightSpeed VCT or Discovery CT 750 HD, General Electric Medical Systems; TOSHIBA Aquilion, TOSHIBA Medical Systems, Tokyo, Japan). To avoid the effects of respiratory artifacts, images were acquired with the patient in a fully inspiratory state. Parameters for CT scans included: a tube voltage of 120 kVp; automatic mA configurations (tube current between 200–350 mA, noise index at 13; pitch values of 0.992 or 0.984; a rotation duration of 0.5 s; and a thickness of 5 mm). For enhanced CT scans, iopromide was used as a contrast agent, injected intravenously at 300 mg/mL iodine levels, varying between 80 and 90 mL, with a 2.5 mL/s flow rate, and the images were taken 35 s after the intravenous injection. The reconstruction thicknesses were either 1.25 or 1.0 mm, spaced 0.8 mm apart by a conventional reconstruction algorithm. The images were observed in both the lung window [window width (WW) =1,600 HU; window level (WL) =-600 HU] and the mediastinal window (WW =360 HU; WL =60 HU).

Radiologic features evaluation

The clinical and radiologic features of all enrolled SSPNs were analyzed and processed by Radiology Information System/Picture Archiving and Communication Systems (RIS/PACS). The radiologic features were reviewed by two radiologists (J.N.L. and S.L.C., with 6 and 3 years of experience in diagnosing thoracic tumors, respectively). Disagreements were resolved through consultation with two senior radiologists (L.L.Q. and J.W.W., with 8 and 25 years of experience in diagnosing thoracic tumors, respectively). Radiologic features including nodule size (mean diameter), location, the tumor-lung interface, lobulation, spiculation, air bronchogram, vacuole, pleural traction, and vascular convergence were observed at the lung window; calcification and nodules invisibility were observed at the mediastinal windows.

The tumor-lung interface was defined as the border between the lesion and normal lung parenchyma, which was classified as clear and smooth, clear and rough, and unclear/halo sign. A clear and smooth tumor-lung interface was clear and flat, with or without lobation (*Figure 1A*). Unlike the smooth tumor-lung interface, clear and rough indicated clear but irregular or spiculated interface (*Figure 1B*). Unclear/halo sign demonstrated glass opacity around the lesion (*Figure 1C*). Lobulation is defined as part of the lesion having a wavy or scalloped surface (13). According to the ratio of the chord arc distance to chord length, the lobation sign was divided into three categories: shallow (a ratio of ≤ 0.2), medium (a ratio of 0.2 to 0.4), and deep (a ratio of ≥ 0.4) lobation (*Figure 1D-1F*). Spiculation was generally divided into two categories: short and long spiculation; the former fine and short, length < 1 cm, width 1 mm; the latter thick and long, length 1–3 cm, width 1–2 mm (*Figure 1B, 1G*). A vacuole is defined as a small area of round or oval air attenuation within the nodule (*Figure 1B*). Air bronchogram is the presence of air-filled bronchi in the nodule (*Figure 1H*). When a nodule is visible at the mediastinal window, it indicates that the nodule can be observed both at the lung window and the mediastinal window (*Figure 1I, 1J*). A SSPN is invisible at the mediastinal window, it indicates that the nodule can be observed at the lung window, but not at the mediastinal window (*Figure 1K, 1L*).

Pathological diagnosis

The pathological diagnosis and categorization of

SSPNs were confirmed based on the new World Health Organization (WHO) pulmonary tumor classification, 2021 edition (14). Surgical samples served as the basis for the ultimate pathological assessments. All histological preparations and analyses were conducted by two experienced pathologists, each having over two decades of expertise in pathological diagnoses. Disagreements were resolved and settled either through collective agreement or following discussions with a third pathologist.

Statistical analysis

All statistical analyses were performed with the SPSS software (version 26.0). Continuous variables were analyzed with the independent samples *t*-test and the Wilcoxon rank-sum test. The categorical variables were compared with the χ^2 test and Fisher's exact test. Measurement data were presented as the mean \pm standard deviation (SD) or median (25th, 75th). Count data were expressed as percentages. The bilateral *P* value < 0.05 was considered statistically significant. Variables with $P < 0.05$ in the univariate analysis were included in the multivariable logistic regression analysis to determine the independent risk factors. A receiver operating characteristic (ROC) curve was used to evaluate the performance of the model. Moreover, the model was validated by the internal set and external set, respectively.

Results

Clinical and radiological characteristics of SSPNs in the training set and independent risk factors for malignant SSPNs

The clinical and radiological characteristics of enrolled SSPNs in the training set are demonstrated in *Table 2*. The training cohort consisted of 183 patients: 73 males (57.6 \pm 11.6 years) and 110 females (54.3 \pm 9.1 years). In this study, seven clinical and eleven CT features were analyzed. The univariate analysis demonstrated significant differences in the tumor-lung interface ($P < 0.001$), lobulation ($P = 0.003$), spiculation ($P < 0.001$), air bronchogram ($P = 0.001$), vacuole ($P = 0.006$), pleural traction ($P = 0.002$), and invisible at the mediastinal window ($P = 0.04$) between benign and malignant groups. Multivariable logistic regression analysis showed that characteristics of the tumor-lung interface ($P = 0.002$), spiculation ($P = 0.04$), air bronchogram ($P = 0.047$), and invisible at the mediastinal window ($P = 0.003$) were




Figure 1 CT morphological characteristics and pathological subtypes of SSPNs. (A) A 38-year-old woman with no clinical symptoms. Axial CT scan shows 10.0 mm SSPN located in RLL, with clear and smooth tumor-lung interface. The nodule was pathologically confirmed as a chondroma by wedge resection. (B) A 58-year-old woman with no clinical symptoms. Axial CT scan shows 9.5 mm SSPN located in RUL, with clear and rough tumor-lung interface, short spiculation, vacuole. The nodule was pathologically confirmed as adenocarcinoma by lobectomy. (C) A 44-year-old woman, cough for more than 4 months. Axial CT scan shows 8.5 mm SSPN located in LLL, with unclear tumor-lung interface/halo sign. The nodule was pathologically confirmed to be adenocarcinoma by wedge resection. (D) A 55-year-old man with no clinical symptoms. Axial CT scan shows 9.5 mm SSPN located in RLL, with clear and smooth tumor-lung interface, shallow lobation. The nodule was pathologically confirmed as a chondromatous hamartoma by wedge resection. (E) A 63-year-old man with no clinical symptoms. Axial CT scan shows 7.5 mm SSPN located in RML, with clear and smooth tumor-lung interface, medium lobation. The nodule was pathologically confirmed as a hamartoma by wedge resection. (F) A 65-year-old woman with no clinical symptoms. Axial CT scan shows 7.5 mm SSPN located in LLL, with clear and rough tumor-lung interface and deep lobation. The nodule was pathologically confirmed to be adenocarcinoma by lobectomy. (G) A 52-year-old woman with no clinical symptoms. Axial CT scan shows 5.0 mm SSPN located in LUL, with clear and rough tumor-lung interface, long spiculation. The nodule was pathologically confirmed as fibroplasia by sublobar resection. (H) A 59-year-old man with no clinical symptoms. Axial CT scan shows 8.5 mm SSPN located in LUL, with clear and rough tumor-lung interface, deep lobation, air bronchogram and pleural traction. The nodule was pathologically confirmed as adenocarcinoma by sublobar resection. (I,J) A 27-year-old woman with no clinical symptoms. Axial CT scan shows 10.0 mm SSPN located in LUL, with clear and smooth tumor-lung interface, shallow lobation, visible at the mediastinal window (J). The nodule was pathologically confirmed as a chondromatous hamartoma by wedge resection. (K,L) A 67-year-old woman with no clinical symptoms. Axial CT scan shows 6.5 mm SSPN located in RUL, with unclear tumor-lung interface/halo sign tumor-lung interface, deep lobation, and invisible at the mediastinal window (L). The nodule was pathologically confirmed to be adenocarcinoma by lobectomy. CT, computed tomography; SSPNs, sub-centimeter solid pulmonary nodules; RLL, right lower lobe; RUL, right upper lobe; LLL, left lower lobe; RML, right middle lobe; LUL, left upper lobe.

independent risk factors of malignant SSPNs. The AUCs of the independent predictors for differentiating benign and malignant SSPNs ranged from 0.546 to 0.690 (Figure 2).

Model construction and its internal and external validation

The clinical and radiological characteristics of SSPNs in the internal and external validation sets are demonstrated in the

Tables 3,4. The prediction model for distinguishing benign and malignant SSPNs was established based on the results of multivariable logistic regression analysis.

ROC analysis revealed that the model's area under the curve (AUC) value was 0.875 [95% confidence interval (CI): 0.818, 0.933] for the training set (Figure 3). The AUCs in the internal and external validation set were 0.781 (95% CI: 0.664, 0.897) and 0.873 (95% CI: 0.791, 0.955), respectively; the sensitivity and specificity were 66.7%

Table 2 The clinical and radiological characteristics of enrolled SSPNs in the training set

Characteristics	Benign (n=70)	Malignant (n=113)	P value	Multivariate logistic regression analysis	
				OR	P value
Gender, n (%)			0.77	–	–
Male	27 (38.6)	46 (40.7)		–	–
Female	43 (61.4)	67 (59.3)		–	–
Age (years), mean ± SD	54.5±10.2	56.3±10.3	0.25	–	–
Symptom, n (%)	20 (28.6)	21 (18.6)	0.12	–	–
Smoking history, n (%)	13 (18.6)	27 (23.9)	0.40	–	–
Family cancer history, n (%)	26 (37.1)	40 (35.4)	0.81	–	–
Abnormal CEA level, n (%)	1 (1.4)	5 (4.4)	0.41	–	–
Previous history of extra-thoracic cancer 5 years ago, n (%)	0 (0.0)	2 (1.8)	0.53	–	–
Size (mm), median (25th, 75th)	8.0 (7.0–9.5)	8.5 (7.3–10.0)	0.12	–	–
Location, n (%)			0.86	–	–
LUL	17 (24.3)	30 (26.5)		–	–
RUL	17 (24.3)	23 (20.4)		–	–
RML	8 (11.4)	11 (9.7)		–	–
LLL	11 (15.7)	24 (21.2)		–	–
RLL	17 (24.3)	25 (22.1)		–	–
The tumor-lung interface, n (%)			<0.001*	–	0.002*
Clear and smooth	34 (48.6)	4 (3.5)		Reference	
Clear and rough	25 (35.7)	91 (80.5)		40.853	0.001*
Unclear/halo sign	11 (15.7)	18 (15.9)		17.206	0.01*
Lobulation, n (%)			0.003*	–	0.57
None	24 (34.3)	23 (20.4)		Reference	
Shallow	7 (10.0)	6 (5.3)		0.903	0.92
Medium	6 (8.6)	2 (1.8)		0.225	0.22
Deep	33 (47.1)	82 (72.6)		1.148	0.79
Spiculation, n (%)			<0.001*	–	0.04*
None	62 (88.6)	66 (58.4)		Reference	
Short	7 (10.0)	47 (41.6)		3.638	0.01*
Long	1 (1.4)	0 (0.0)		0.000	>0.99
Air bronchogram, n (%)	2 (2.9)	24 (21.2)	0.001*	5.005	0.047*
Vacuole, n (%)	6 (8.6)	28(24.8)	0.006*	3.094	0.051
Pleural traction, n (%)	20 (28.6)	58 (51.3)	0.002*	1.505	0.35
Vascular convergence, n (%)	1 (1.4)	11 (9.7)	0.06	–	–
Calcification, n (%)	2 (2.9)	0 (0.0)	0.15	–	–
Invisible at the mediastinal window, n (%)	1 (1.4)	12 (10.6)	0.04*	88.599	0.003*

The differences were assessed by the independent samples *t*-test and Wilcoxon Rank Sum test or Pearson χ^2 test and Fisher's exact test, as appropriate. *, $P < 0.05$. SSPNs, sub-centimeter solid pulmonary nodules; OR, odds ratio; SD, standard deviation; CEA, carcinoembryonic antigen; LUL, left upper lobe; RUL, right upper lobe; RML, right middle lobe; LLL, left lower lobe; RLL, right lower lobe.




Figure 2 ROC analysis of independent predictors. The AUC of the tumor-lung interface, spiculation, air bronchogram, invisible at the mediastinal window, was 0.690 (95% CI: 0.602, 0.779), 0.648 (95% CI: 0.568, 0.728), 0.592 (95% CI: 0.510, 0.674), 0.546 (95% CI: 0.462, 0.630). ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval.

and 83.3% for the internal validation data, and 100.0% and 61.0% for the external validation data, respectively (Figures 4,5).

Discussion

The differentiation between benign and malignant SSPNs remains difficult in clinical practice. Earlier diagnosis could improve patient survival and prognosis. In this study, we explored on CT and clinical features of SSPNs and established and validated a prediction model to assist in distinguishing malignant and benign SSPNs. Multivariable logistic regression analysis showed that the tumor-lung interface, spiculation, air bronchogram, and invisible at the mediastinal window were independent risk factors of malignant SSPNs. The AUCs in the internal and external validation set were (0.781; 95% CI: 0.664, 0.897) and (0.873; 95% CI: 0.791, 0.955), respectively; the sensitivity and specificity were 66.7% and 83.3% for the internal validation data, and 100.0% and 61.0% for the external validation data, respectively.

In this study, a clear and rough tumor-lung interface

conferred a 40.9-fold increased risk of malignancy than a clear and smooth nodule, which is much higher than a previous study (15). The previous study showed that poorly defined border increased the risk of lung cancer by 6.6-fold. Perhaps it is because this study only included SSPNs, while the previous study included both ground-glass nodules and solid nodules. Halo sign presents as an area of ground-glass attenuation surrounding a solid pulmonary nodule and it was usually considered pulmonary hemorrhage (16). In this study, the incidence of halo sign was slightly higher in malignant SSPNs, which may be caused by tumor invasion of the surrounding tissue or a lepidic pattern of the tumor margins. Therefore, a small nodule with a halo sign should be alert to the possibility of malignancy.

It should be noted that SSPNs with clear and smooth tumor-lung interfaces are not enough to be considered as benign, and they may be highly malignant. Proximately 20% to 30% of pulmonary nodules with well-defined, and smooth borders are malignant (17). In a recent study, Hu *et al.* (18) reported two cases of SSPNs manifesting smooth edges were small cell lung cancers (SCLCs), which diverge from those of larger SCLCs. In this study, six malignant SSPNs with clear and smooth borders tended to be ball or oval. One was SCLC, and the remaining five were adenocarcinomas. Thus, a sub-centimeter nodule with a clear and well-defined border is not definitely benign, and it is also necessary to observe other malignant imaging features and the growth rate for a comprehensive assessment.

As reported, spiculation signs or air bronchogram effectively distinguish benign and malignant nodules (19,20). In this study, SSPNs with short spiculation signs or air bronchogram are prone to be malignant. Generally, solid nodules are visible at the mediastinal window, while, invisible at the mediastinal window is an independent predictor for malignant SSPNs in this study. It could be a result of a lepidic growth pattern or the gradual accumulation of cells during the growth. Moreover, compared with previous studies, located in the upper lobe (15,21-24), larger size (19), and lobulation (25) were not strongly correlated with malignancy. Generally, older age and abnormal carcinoembryonic antigen (CEA) are related to malignant nodules (25,26), however, in this study, neither age nor CEA level is independent predictor. The possible reasons for the results are as follows: compared to traditional larger lung cancers, the small size of SSPNs, makes these features less notable; the different characteristics of the participants enrolled. These results

Table 3 The clinical and radiological characteristics of SSPNs in the internal validation set

Characteristics	Benign (n=30)	Malignant (n=48)	P value
Gender, n (%)			0.57
Male	13 (43.3)	24 (50.0)	
Female	17 (56.7)	24 (50.0)	
Age (years), mean ± SD	55.7±11.6	57.5±8.7	0.44
Symptom, n (%)	1 (3.3)	13 (27.1)	0.008*
Smoking history, n (%)	7 (23.3)	13 (27.1)	0.71
Family cancer history, n (%)	10 (33.3)	15 (31.2)	0.85
Abnormal CEA level, n (%)	1 (3.3)	4 (8.3)	0.64
Previous history of extra-thoracic cancer 5 years ago, n (%)	0 (0.0)	2 (4.2)	0.52
Size (mm), median (25th, 75th)	8.3 (6.4–9.6)	9.0 (7.6–10.0)	0.045*
Location, n (%)			0.45
LUL	3 (10.0)	11 (22.9)	
RUL	8 (26.7)	8 (16.7)	
RML	3 (10.0)	2 (4.2)	
LLL	8 (26.7)	15 (31.3)	
RLL	8 (26.7)	12 (25.0)	
The tumor-lung interface, n (%)			<0.001*
Clear and smooth	14 (46.7)	2 (4.2)	
Clear and rough	12 (40.0)	37 (77.1)	
Unclear/halo sign	4 (13.3)	9 (18.8)	
Lobulation, n (%)			<0.001*
None	10 (33.3)	2 (4.2)	
Shallow	9 (30.0)	3 (6.3)	
Medium	1 (3.3)	4 (8.3)	
Deep	10 (33.3)	39 (81.3)	
Spiculation, n (%)			0.02*
None	23 (76.7)	28 (58.3)	
Short	5 (16.7)	20 (41.7)	
Long	2 (6.7)	0 (0.0)	
Air bronchogram, n (%)	2 (6.7)	17 (35.4)	0.004*
Vacuole, n (%)	2 (6.7)	12 (25.0)	0.04*
Pleural traction, n (%)	8 (26.7)	28 (58.3)	0.006*
Vascular convergence, n (%)	0 (0.0)	3 (6.3)	0.28
Calcification, n (%)	1 (3.3)	1 (2.1)	>0.99
Invisible at the mediastinal window, n (%)	2 (6.7)	3 (6.3)	>0.99

The differences were assessed by the independent samples *t*-test and Wilcoxon Rank Sum test or Pearson χ^2 test and Fisher's exact test, as appropriate. *, $P < 0.05$. SSPNs, sub-centimeter solid pulmonary nodules; SD, standard deviation; CEA, carcinoembryonic antigen; LUL, left upper lobe; RUL, right upper lobe; RML, right middle lobe; LLL, left lower lobe; RLL, right lower lobe.

Table 4 The clinical and radiological characteristics of SSPNs in the external validation set

Variables	Benign (n=41)	Malignant (n=28)
The tumor-lung interface, n (%)		
Clear and smooth	30 (73.2)	2 (7.1)
Clear and rough	9 (22.0)	22 (78.6)
Unclear/halo sign	2 (4.9)	4 (14.3)
Spiculation, n (%)		
None	35 (85.4)	11 (39.3)
Short	6 (14.6)	17 (60.7)
Long	0 (0.0)	0 (0.0)
Air bronchogram, n (%)		
Invisible at the mediastinal window, n (%)	4 (9.8)	1 (3.6)

SSPNs, sub-centimeter solid pulmonary nodules.




Figure 3 ROC analysis of model in the training cohort for predicting malignancy of SSPNs. AUC was 0.875 (95% CI: 0.818, 0.933). ROC, receiver operating characteristic; SSPNs, sub-centimeter solid pulmonary nodules; AUC, area under the curve; CI, confidence interval.

suggest that small nodules differ from traditional larger nodules both clinically and radiologically.

There are overlaps between benign and malignant SSPNs (27,28). The presence of lobulation or spiculation in granuloma nodules usually confuses our judgment, which makes the diagnoses more challenging and intricate. Because of excavating numerous quantitative imaging features with high throughput of radiomics




Figure 4 ROC analysis of model in the internal validation cohort for predicting malignancy of SSPNs. AUC was 0.781 (95% CI: 0.664, 0.897). ROC, receiver operating characteristic; SSPNs, sub-centimeter solid pulmonary nodules; AUC, area under the curve; CI, confidence interval.




Figure 5 ROC analysis of model in the external validation cohort for predicting malignancy of SSPNs. AUC was 0.873 (95% CI: 0.791, 0.955). ROC, receiver operating characteristic; SSPNs, sub-centimeter solid pulmonary nodules; AUC, area under the curve; CI, confidence interval.

and automatically learning features at multiple levels of abstraction of deep learning (29,30), some scholars have attempted to apply them for establishing prediction models in the recent studies (23,28,31,32). Their prediction models have achieved relatively good results in predicting malignancy or distinguishing between benign and malignant lesions. Nonetheless, due to poor reproducibility in radiomics, makes them difficult to be widely applied in clinical practice (33). Hence, we believe traditional imaging is still critical.

Due to the low probability of malignancy but high

degree of malignancy of solid nodules, the clinical method for SSPNs mainly relies on careful attention on CT follow-up observation for further treatment. Various guidelines recommend 12-month follow-up intervals for solid nodules <6 mm, 6–12 months follow-up intervals for solid nodules 6–8 mm, and 3 months for solid nodules ≥8 mm of patients with high-risk factors (34–36). A retrospective study discovered solid nodules maintaining stability of within a 3-month follow-up interval is not strong evidence for the diagnosis of benign nodules and requires continuous attention (37). Therefore, in clinical practice, for suspected SSPNs, the observation window should be appropriately extended, and early diagnosis and surgical treatment should be carried out.

There were several limitations in this study. Firstly, the study was retrospective with relatively small sample size. Secondly, this study did not include genetic mutations information. Finally, only one external validation dataset was available in this study and more validations should be conducted.

Conclusions

In summary, tumor-lung interface, spiculation, air bronchogram and invisible at the mediastinal window are independent predictors for distinguishing malignant from benign SSPNs. This study established a prediction model based on CT features and validated its performance using data from two centers, which may help in the early diagnosis of lung cancer and improve patient prognosis.

Acknowledgments

Funding: This work was supported by the Beijing National Science Foundation (grant No. 7222148), the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant No. 2021-I2M-C&T-B-065), the National Natural Science Foundation of China (grant No. 81971616), and the Special Research Fund for Central Universities, Peking Union Medical College (grant No. 3332022025).

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1943/rc>

Data Sharing Statement: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1943/dss>

[com/article/view/10.21037/jtd-23-1943/dss](https://jtd.amegroups.com/article/view/10.21037/jtd-23-1943/dss)

Peer Review File: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1943/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1943/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This retrospective study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the institutional ethics board of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (NCC2021C-283) and The Fourth Hospital of Hebei Medical University was informed and agreed with the study. Informed consent was waived as this was a retrospective study and subjects were assured of privacy and identifying information.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
2. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. *Chest* 2017;151:193-203.
3. National Lung Screening Trial Research Team; Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395-409.

4. Fan L, Wang Y, Zhou Y, et al. Lung Cancer Screening with Low-Dose CT: Baseline Screening Results in Shanghai. *Acad Radiol* 2019;26:1283-91.
5. Kim YW, Kang HR, Kwon BS, et al. Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers. *Eur Respir J* 2020;56:2000177.
6. Hattori A, Suzuki K, Matsunaga T, et al. What is the appropriate operative strategy for radiologically solid tumours in subcentimetre lung cancer patients?†. *Eur J Cardiothorac Surg* 2015;47:244-9.
7. Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. *AJR Am J Roentgenol* 2002;178:1053-7.
8. Sakurai H, Nakagawa K, Watanabe S, et al. Clinicopathologic features of resected subcentimeter lung cancer. *Ann Thorac Surg* 2015;99:1731-8.
9. Sun K, You A, Wang B, et al. Clinical T1aN0M0 lung cancer: differences in clinicopathological patterns and oncological outcomes based on the findings on high-resolution computed tomography. *Eur Radiol* 2021;31:7353-62.
10. Mazzone PJ, Lam L. Evaluating the Patient With a Pulmonary Nodule: A Review. *JAMA* 2022;327:264-73.
11. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. *Arch Intern Med* 1997;157:849-55.
12. Gould MK, Ananth L, Barnett PG, et al. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. *Chest* 2007;131:383-8.
13. Chu ZG, Li WJ, Fu BJ, et al. CT Characteristics for Predicting Invasiveness in Pulmonary Pure Ground-Glass Nodules. *AJR Am J Roentgenol* 2020;215:351-8.
14. WHO Classification of Tumours Editorial Board. Thoracic Tumours. WHO Classification of Tumours. 5th edition. 2021. Available online: <https://tumourclassification.iarc.who.int/>
15. Liu Y, Wang H, Li Q, et al. Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. *Radiology* 2018;286:298-306.
16. Parrón M, Torres I, Pardo M, et al. The halo sign in computed tomography images: differential diagnosis and correlation with pathology findings. *Arch Bronconeumol* 2008;44:386-92.
17. Wahidi MM, Govert JA, Goudar RK, et al. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132:94S-107S.
18. Hu B, Ren W, Feng Z, et al. Correlation between CT imaging characteristics and pathological diagnosis for subcentimeter pulmonary nodules. *Thorac Cancer* 2022;13:1067-75.
19. She Y, Zhao L, Dai C, et al. Development and validation of a nomogram to estimate the pretest probability of cancer in Chinese patients with solid solitary pulmonary nodules: A multi-institutional study. *J Surg Oncol* 2017;116:756-62.
20. Jacob M, Romano J, Ara Jo D, et al. Predicting lung nodules malignancy. *Pulmonology* 2022;28:454-60.
21. Chen X, Feng B, Chen Y, et al. A CT-based radiomics nomogram for prediction of lung adenocarcinomas and granulomatous lesions in patient with solitary sub-centimeter solid nodules. *Cancer Imaging* 2020;20:45.
22. Kinsey CM, Estepar RS, Zhao Y, et al. Invasive adenocarcinoma of the lung is associated with the upper lung regions. *Lung Cancer* 2014;84:145-50.
23. Wang S, Zhou L, Li X, et al. A Novel Deep Learning Model to Distinguish Malignant Versus Benign Solid Lung Nodules. *Med Sci Monit* 2022;28:e936830.
24. Chu ZG, Zhang Y, Li WJ, et al. Primary solid lung cancerous nodules with different sizes: computed tomography features and their variations. *BMC Cancer* 2019;19:1060.
25. Liu M, Zhou Z, Liu F, et al. CT and CEA-based machine learning model for predicting malignant pulmonary nodules. *Cancer Sci* 2022;113:4363-73.
26. Zhang R, Tian P, Chen B, et al. Predicting Lung Cancer Risk of Incidental Solid and Subsolid Pulmonary Nodules in Different Sizes. *Cancer Manag Res* 2020;12:8057-66.
27. He C, Liu J, Li Y, et al. Quantitative parameters of enhanced dual-energy computed tomography for differentiating lung cancers from benign lesions in solid pulmonary nodules. *Front Oncol* 2022;12:1027985.
28. Feng B, Chen X, Chen Y, et al. Radiomics nomogram for preoperative differentiation of lung tuberculoma from adenocarcinoma in solitary pulmonary solid nodule. *Eur J Radiol* 2020;128:109022.
29. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol* 2017;14:749-62.
30. Sun W, Zheng B, Qian W. Automatic feature learning using multichannel ROI based on deep structured algorithms for computerized lung cancer diagnosis.

- Comput Biol Med 2017;89:530-9.
31. Xu Y, Lu L, E LN, et al. Application of Radiomics in Predicting the Malignancy of Pulmonary Nodules in Different Sizes. *AJR Am J Roentgenol* 2019;213:1213-20.
 32. Zhang R, Sun H, Chen B, et al. Developing of risk models for small solid and subsolid pulmonary nodules based on clinical and quantitative radiomics features. *J Thorac Dis* 2021;13:4156-68.
 33. Wu G, Jochems A, Refaee T, et al. Structural and functional radiomics for lung cancer. *Eur J Nucl Med Mol Imaging* 2021;48:3961-74.
 34. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. *Radiology* 2017;284:228-43.
 35. American College of Radiology. Lung-RADS. 2022 Assessment Categories. 2022.11. Available online: <https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads>
 36. Wood DE, Kazerooni EA, Aberle D. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Guidelines Version 1.2023 Lung Cancer Screening. 2022.10.26. Available online: <https://nccnchina.org.cn/>
 37. Byrne SC, Hammer MM. Malignant Nodules Detected on Lung Cancer Screening CT: Yield of Short-Term Follow-Up CT in Showing Nodule Growth. *AJR Am J Roentgenol* 2022;219:735-41.

Cite this article as: Cui SL, Qi LL, Liu JN, Li FL, Chen JQ, Cheng SN, Xu Q, Wang JW. A prediction model based on computed tomography characteristics for identifying malignant from benign sub-centimeter solid pulmonary nodules. *J Thorac Dis* 2024;16(7):4238-4249. doi: 10.21037/jtd-23-1943